Search Results

Molecular Templates, Inc. today provided an update on its clinical-stage programs.

Molecular Templates, Inc. today provided an update on its programs.

Molecular glue degraders are gaining traction in the clinic as well as funding from Big Pharma, with their potential to treat previously “undruggable” cancers and immunological diseases. Here are five clinical programs worth keeping an eye on.

Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”) today reported financial results for the fourth quarter and full year ended December 31, 2023.

Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (“ETBs”), to create novel therapies with potent differentiated mechanisms of action, today reported financial results and business updates for the first quarter of 2024.

It’s the latest Big Pharma deal for molecular glue technology and Novartis’ second with Orionis Biosciences, after first linking up in March 2020. The backloaded agreement will see Novartis pay $40 million upfront.

Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company developing novel therapeutics with potent and differentiated mechanisms of action for cancer, announced participation in the upcoming Oppenheimer 34th Annual Healthcare Life Sciences Conference.

Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”) today reported financial results and business updates for the third quarter of 2023.

Molecular Templates, Inc. announced participation in the following upcoming investor conferences.

Degron Therapeutics will have stiff competition in immunology, as Novartis inked a $5.7 billion agreement with Monte Rosa Therapeutics last year to develop molecular glues for undisclosed immune-mediated conditions.